Evaluation of the effects of three designs of oxygenators with integrated filters on clinical and haematological outcomes at an Australasian cardiothoracic unit

Abstract

Introduction:

Cardiopulmonary bypass (CPB) machines have oxygenators with integrated filters and unique biocompatible coatings to combat systemic inflammatory response syndrome (SIRS) and mitigate coagulopathy. Contemporary oxygenators have undergone comparative studies; however, our study aimed to identify the most appropriate oxygenator for our regional Cardiothoracic unit in Australasia.

Methods:

A prospective audit consecutively recruited one-hundred and fifty patients undergoing cardiac surgery at Waikato Hospital, New Zealand between the periods of 29th January 2018 and 31st July 2018. Fifty patients were recruited for each oxygenator arm: Sorin INSPIRE’ (Group-S); Terumo CAPIOX’FX (Group-T); and Medtronic Affinity Fusion’ (Group-M). The clinical outcomes were transfusions, chest drain output, reoperation and length of hospital stay (LOHS). Routine blood testing protocol included: haemoglobin, protein, albumin, white cell count (WCC), C-reactive protein (CRP), platelet count and coagulations tests including international normalized ratio (INR).

Results:

Comparing Groups S, T and M there was no statistical difference in chest drain output (650 vs. 500 vs. 595 ml respectively, p = 0.45), transfusions (61 vs. 117 vs. 70 units, p = 0.67), reoperation (6 vs. 8 vs. 12%, p = 0.99) and LOHS (median 7.4 vs. 7.6 vs. 9.5 days, p = 0.42). Group-T had fewer SIRS cases but similar increase in CRP (p = 0.12) and WCC (p = 0.35). Group-M had a significant rise in post-op INR (p = 0.005) but no associated increase in chest drain output (p = 0.62). Group-S and -M required more 4%-albumin and Group-T had more transfusions. Only fresh frozen plasma (FFP) and red blood cell (RBC) transfusion had a significant relationship with LOHS (p < 0.05).

Conclusion:

Biochemically, there was slight difference among the oxygenators which did not translate into clinical difference in outcomes. The oxygenator design and perfusionist choice aided in our decision-making process.

Keywords

Cardiopulmonary bypass oxygenators bioactive coating biopassive coating

Get full access to this article

View all access options for this article.

References

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis”. Crit Care Med. 20 (6): 864–874. 1992

Al-Fares

Pettenuzzo

Sorbo

. Extracorporeal life support and systemic inflammation. Intensive Care Med Exp 2019; 7(1): 46.

Landis

Brown

Fitzgerald

et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol. 2014 Sep; 46(3): 197–211.

Schiel

Burns

Nogawa

, et al. X coating: A new biopassive polymer coating. [online] Terumo-cvs.com. Available at:, http://www.terumo-cvs.com/doc/Schiel_CanadianPerNTCanadienne_11_No2.pdf (2001, Accessed 3 Jan. 2020.

Shann

Likosky

Murkin

, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 2006; 132: 283–290.

Salis

Mazzanti

Merli

, et al. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22: 814–822.

Ontaneda

Annich

. Novel surfaces in extracorporeal membrane oxygenation circuits. Front Med 2018; 5: 321.

Onorati

Santini

Raffin

, et al. Clinical evaluation of new generation oxygenators with integrated arterial line filters for cardiopulmonary bypass. Artif Organs 2012; 36(10): 875–885.

Ranucci

Balduini

Ditta

, et al. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 2009; 87: 1311–1319.

10.

Livanovamediaprod.azureedge.net (2016). INSPIRE™ 8 P.H.I.S.I.O. [online] Available at: https://livanovamediaprod.azureedge.net/livanova-media/livanova-public/media/resources01/livanova_inspire_8_broch_09295-130-b.pdf?ext=.pdf [Accessed 4 Sep. 2019].

11.

CAPIOX® FX Advance: Oxygenator with Integrated Arterial Filter and Hardshell Reservoir [Internet] . Terumo Cardiovascular Group. 2015 [cited 5 September 2019]. Available from: https://www.terumo-cvs.com/doc/863551_CAPIOX-FX-Advance-Brochure_DEC2015_FINAL.pdf

12.

Affinity Fusion™ Oxygenation System - Product Overview [Internet] . Global.medtronic.com. 2017 [cited 4 September 2019]. Available from: https://global.medtronic.com/xg-en/healthcare-professionals/products/cardiovascular/cardiopulmonary/affinity-fusion-oxygenation-system.html

13.

Pagano

Milan

Milojevic

Meesters

, et al. EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardio-Thoracic Surg 2017; 53(1): 79–111.

14.

Mirrow

Zittermann

Koertke

, et al. Heparin-coated extracorporeal circulation in combination with low dose systemic heparinization reduces early postoperative blood loss in cardiac surgery. J CardioVasc Surg 2008; 49: 277–284.

15.

McCarthy

Yared

Foster

, et al. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. Ann Thorac Surg 1999; 67: 1268–1273.

16.

Mangoush

Purkayastha

Haj-Yahia

, et al. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur J Cardiothorac Surg 2007; 31: 1058–1069.

17.

Thiara

Andersen

Videm

, et al. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion 2010; 25: 9–16.

18.

Sohn

Marcoux

Mycyk

et al. The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion 2009; 24: 231–237.

19.

Salis

Mazzanti

Merli

, et al. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22: 814–822.

20.

Deppe

A-C

Weber

Zimmermann

, et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016; 203(2): 424–433.

21.

Izuha

Hattori

Igari

, et al. Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material. J Artif Organs 2005; 8: 41–46.

22.

Noguchi

Eishi

Tada

, et al. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass. Ann Thorac Cardiovasc Surg 2003; 9(1): 22–28.

23.

Stanzel

Henderson

. Clinical evaluation of contemporary oxygenators. Perfusion 2016; 31(1): 15–25.

24.

Paar

Rossman

Nusshold

, et al. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One 2017; 12(8): e0182997.

25.

Montazerghaem

Safaie

Samiei Nezhad

. Body mass index or serum albumin levels: which is further prognostic following cardiac surgery?. J Cardiovasc Thorac Res 2014; 6(2): 123–126.

26.

Skhirtladze

Base

Lassnigg

, et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer’s lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth 2014; 112(2): 255–264.

27.

Rabin

Meyenburg

Lowery

, et al. Restricted albumin utilization is safe and cost effective in a cardiac surgery intensive care unit. Ann Thorac Surg 2017; 104: 42–48.